title: Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities.
abstract: This report describes the use of three quantitative structure-activity relationship (QSAR) programs to predict drug-related cardiac adverse effects (AEs), BioEpisteme, MC4PC, and Leadscope Predictive Data Miner. QSAR models were constructed for 9 cardiac AE clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes) and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders). The models were based on a database of post-marketing AEs linked to 1632 chemical structures, and identical training data sets were configured for three QSAR programs. Model performance was optimized and shown to be affected by the ratio of the number of active to inactive drugs. Results revealed that the three programs were complementary and predictive performances using any single positive, consensus two positives, or consensus three positives were as follows, respectively: 70.7%, 91.7%, and 98.0% specificity; 74.7%, 47.2%, and 21.0% sensitivity; and 138.2, 206.3, and 144.2 chi(2). In addition, a prospective study using AE data from the U.S. Food and Drug Administration's (FDA's) MedWatch Program showed 82.4% specificity and 94.3% sensitivity. Furthermore, an external validation study of 18 drugs with serious cardiotoxicity not considered in the models had 88.9% sensitivity.
authors: GlobalNet Services, 11820 Parklawn Drive, Rockville, MD 20852, USA.
authors: Anna A
authors: AA
authors: Frid
authors: Edwin J
authors: EJ
authors: Matthews
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology*; D016000:Cluster Analysis; D003198:Computer Simulation; D016208:Databases, Factual; D004348:Drug Labeling; D064420:Drug-Related Side Effects and Adverse Reactions / Q000145:classification / Q000453:epidemiology*; D005544:Forecasting; D006321:Heart / Q000187:drug effects*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000145:classification; D011358:Product Surveillance, Postmarketing; D011690:Purkinje Fibers / Q000187:drug effects; D021281:Quantitative Structure-Activity Relationship; D012984:Software; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D004364:Pharmaceutical Preparations